Physician profile
Umeer Ashraf
NPI 1336398213
$3,123.11
in general payments reported to CMS, 2019-2025
27 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $914 · 2021: $70.39 · 2022: $417 · 2023: $82.36 · 2024: $72.90 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493.57 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $465.85 | 2019-2020 | |
| Lilly USA, LLC | $385.67 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $362.44 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.94 | 2019-2022 | |
| Grifols USA, LLC | $162.34 | 2019 | |
| Pfizer INC. | $152.95 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $140.33 | 2019-2025 | Keytruda |
| Mylan Specialty L.P. | $134.69 | 2020-2022 | |
| Amgen INC. | $90.27 | 2019-2020 | |
| Abbott Laboratories | $79.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $75.45 | 2021-2025 | |
| Abbvie INC. | $46.26 | 2022-2025 | |
| Allergan, INC. | $42.96 | 2020 | |
| Valeritas, INC. | $40.14 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $33.95 | 2019 | |
| Gilead Sciences, INC. | $31.59 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $30.72 | 2019-2020 | |
| Daiichi Sankyo INC. | $24.40 | 2019 | |
| G1 Therapeutics, INC. | $21.61 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $20.00 | 2024 | Cosela |
| Sobi, INC | $18.84 | 2024 | |
| Rigel Pharmaceuticals, INC. | $16.24 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.79 | 2019 | |
| Boston Scientific Corporation | $14.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umeer Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.